You are here

BioVaxys Technology Corp.

BioVaxys Technology Corp.
Listing Exchange: 
CSE
Status: 
Active
Industry: 
Life Sciences
Symbol: 
BIOV
CSE Index: 
Currency: 

BioVaxys Technology Corp. is a British Columbia-registered biopharmaceuticals company based in Ontario, Canada that is developing BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stage ovarian cancer. BioVaxys is also exploring vaccines for additional cancers and infectious diseases based on its HapTenix©platform through academic and other collaborations.

You are here

BioVaxys Technology Corp. (BIOV)

SEDAR Information

Company Info

Address
146 Thirtieth Street
Suite 100
Etobicoke, ON M8W 3C4
Canada
Phone
646-452-7000
Email
jpassin@biovaxys.com
Website
https://biovaxys.com/
Listing date
Wednesday, November 21, 2018
Transfer Agent
Odyssey Trust Company
Email
news@biovaxys.com
Auditor
Dale Matheson Carr-Hilton Labonte LLP

Capitalization

Issued & Outstanding: 
210813161
Reserved for Issuance: 
81713573

Company Officers

James Passin, CEO
Kenneth Kovan, COO & President
James Passin, CFO

Bulletins

24/11/2023

2023-1131 - Reinstatement - BioVaxys Technology Corp. (BIOV)

le 24 Novembre/November2023

Effective immediately, BioVaxys Technology Corp. will be reinstated for trading.

The Company has rectified the situation that gave rise to the suspension.

____________________________

À compter d'aujourd'hui, BioVaxys Technology Corp. sera réintégré à la négociation.

La Société a rectifié la situation qui a donné lieu à la suspension.